Inhibition of BODIPY-FL-labeled 3-(3-(4-(3-acrylamido-4-((3-(3,5-dimethoxybenzoyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino)phenyl)piperazin-1-yl)-3-oxopropyl)-5,5-difluoro-7,9-dimethyl-5H-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-4-ium-5-uide probe binding to recombinant FGFR4 (unknown origin) preincubated for 2 hrs followed by probe treatment for 2 hrs by SDS/PAGE and fluorescent gel scanning analysis
Inhibition of FGF19 induced FGFR4 signalling in human Huh-7 cells assessed as inhibition of FRS2alpha phosphorylation at Y436 residue at 10 nM incubated for 1 hr followed by FGF19 stimulation for 10 mins by Western blot analysis
Inhibition of FGF19 induced FGFR4 signalling in human Huh-7 cells assessed as inhibition of AKT phosphorylation at S473 residue incubated for 1 hr followed by FGF19 stimulation for 10 mins by Western blot analysis
Inhibition of FGF19 induced FGFR4 signalling in human Huh-7 cells assessed as inhibition of ERK phosphorylation at T202/Y204 residues incubated for 1 hr followed by FGF19 stimulation for 10 mins by Western blot analysis
Irreversible inhibition of FGFR4 signalling in human Huh-7 cells assessed as inhibition of ERK1/2 phosphorylation at 30 nM preincubated for 1 hr followed by compound washout with PBS and stimulated with FGF19 for 10 mins by Western blot analysis